Having now gained nearly full control of India's Dabur Pharma, Germany-headquartered Fresenius Kabi has said it plans to invest up to 30.0 million euros ($46.8 million) over the next two to three years to double the acquired firm's pharmaceutical active ingredients manufacturing facility in Kolkata. Fresenius first bought a 73.3% stake in the company this spring (Marketletter April 28), and has since achieved a holding of 90.9% through a public offering.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze